Dr. Scher on the Future of the Circulating Tumor Cell Test

Video

Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test

Howard I. Scher, MD, chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering, lead author of the COU-AA-301 trial that investigated circulating tumor cells (CTC), elaborates on the future of the CTC blood test.

Dr. Scher says the CTC blood test has a clearance as an aid to monitoring patients with breast cancer, colorectal cancer, and prostate cancer. Dr. Scher and colleagues wanted to take the test one step further and see if they could develop a biomarker panel that could be used in clinical trials in order to predict early that a drug will prolong life. That requires a test that is analytically validated and also requires a series of clinical trials no different than what's done with drugs of an exploratory phase, phase I, phase II, and phase III. In this case, it requires multiple phase III trials which will show consistent results that the biomarker that is developed is predictive of survival. When that goal is accomplished, they can then apply to the FDA for a formal qualification, which will allow that endpoint to be used in trials in place of survival.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,